The START Center for Cancer Research shared a post on LinkedIn:
“We’re pleased to share that START Lisbon, under the leadership of Dr. André Mansinho, has officially dosed the first European patient in the ongoing Phase 1/2 study evaluating NDI-219216, an investigational WRN helicase inhibitor.
The START Lisbon team activated the site and dosed the first patient less than two weeks later – a testament to the site’s operational excellence and strong collaboration with our partners across Europe.
This study explores a novel approach targeting WRN helicase, an enzyme essential for DNA replication and repair. Tumors with microsatellite instability (MSI-H) depend heavily on WRN function for survival, making WRN inhibition a compelling synthetic lethal strategy across colorectal, gastric, endometrial, and other MSI-H cancers.
We are deeply grateful to the patients and their families who make this research possible. START extends a sincere thank you to the study sponsor Nimbus Therapeutics, the study’s CRO collaborators at Worldwide Clinical Trials, and the entire START Lisbon team for their remarkable work bringing this therapy to patients.
To learn more about the trial, please visit.
Read more post about The START Center for Cancer Research on OncoDaily.